List of Excipients in Branded Drug FYREMADEL

« Back to Dashboard

Generic Drugs Containing FYREMADEL

Company	Ingredient	NDC	Excipient
Ferring Pharmaceuticals Inc	ganirelix acetate	55566-1010	ACETIC ACID
Ferring Pharmaceuticals Inc	ganirelix acetate	55566-1010	MANNITOL
Ferring Pharmaceuticals Inc	ganirelix acetate	55566-1010	SODIUM HYDROXIDE
Ferring Pharmaceuticals Inc	ganirelix acetate	55566-1010	WATER

What are the Most Frequently-Used Excipients in FYREMADEL?

# Of NDCs	Excipient
1	ACETIC ACID
1	MANNITOL
1	SODIUM HYDROXIDE
1	WATER

FYREMADEL Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 25, 2026

FYREMADEL is a preservative-free, single-dose subcutaneous ganirelix acetate injection used to suppress premature luteinizing hormone surges during controlled ovarian stimulation. Its commercial differentiation depends less on the active ingredient than on prefilled-syringe performance, injection tolerability, cold-chain reliability, supply continuity, and fertility-clinic purchasing economics.

The marketed formulation contains ganirelix acetate with mannitol, acetic acid, sodium hydroxide, and water for injection. The product is supplied as 250 mcg in 0.5 mL for subcutaneous administration. The formulation’s main development opportunities are excipient optimization, syringe and needle design, packaging compatibility, and alternative presentations rather than major changes to the active drug chemistry. [1]

What is FYREMADEL and how is it used?

FYREMADEL contains ganirelix acetate, a gonadotropin-releasing hormone antagonist. It is administered during controlled ovarian stimulation in assisted reproductive technology programs.

Attribute	FYREMADEL
Active ingredient	Ganirelix acetate
Strength	250 mcg/0.5 mL
Route	Subcutaneous injection
Dosage form	Sterile injectable solution
Use	Prevention of premature LH surges during controlled ovarian stimulation
Presentation	Single-dose prefilled syringe
Key excipients	Mannitol, acetic acid, sodium hydroxide, water for injection
Regulatory pathway	FDA-approved prescription drug
Therapeutic market	Fertility treatment and assisted reproductive technology

The product is administered in a low-volume injection format. That limits the practical amount of excipient that can be added without affecting osmolality, viscosity, injection force, or patient comfort.

What excipients protect the FYREMADEL formulation?

The current formulation uses a relatively narrow excipient system:

Excipient	Likely formulation function
Mannitol	Tonicity adjustment and possible stabilization support
Acetic acid	Acid component of the pH-control system
Sodium hydroxide	pH adjustment
Water for injection	Injectable vehicle

The publicly available prescribing information identifies these excipients but does not assign each one a separate functional claim. The formulation is a clear, sterile solution intended for single-dose administration. [1]

Why mannitol is commercially relevant

Mannitol is useful in small-volume parenteral formulations because it can adjust tonicity without introducing a preservative. Its use may also help maintain a more physiologically acceptable injection environment.

For a follow-on developer, mannitol creates several formulation constraints:

• Concentration affects osmolality.
• Excessive concentration can increase injection discomfort.
• Solid-state or solution behavior must remain consistent through refrigerated storage.
• The excipient must be compatible with the syringe barrel, stopper, needle adhesive, and sterilization process.

Mannitol is widely available and generally does not create a high raw-material barrier. The commercial value lies in controlling grade, supplier qualification, endotoxin profile, particulate burden, and supply redundancy.

Why acetate buffering matters

The formulation uses acetic acid and sodium hydroxide rather than a conventional phosphate buffer system. This creates potential opportunities for development teams evaluating:

• pH stability;
• precipitation risk;
• peptide or small-molecule degradation;
• container-closure compatibility;
• extractables and leachables;
• injection-site tolerability.

A buffer substitution would require a full comparability package. For a product administered in fertility treatment, an excipient change could affect regulatory classification, clinical bridging requirements, stability data, and physician acceptance.

What formulation patents protect FYREMADEL?

The commercial protection for FYREMADEL should be separated into four categories: active-ingredient patents, formulation patents, method-of-use patents, and device or packaging rights.

The FDA label identifies the product and its formulation but does not, by itself, establish a broad patent estate. The Orange Book should be reviewed for any patents listed against the specific FDA application. FDA Orange Book listings are product-specific and can differ from patents that remain enforceable under general patent law. [2]

Patent categories relevant to ganirelix injection

Patent category	Relevance to FYREMADEL
Ganirelix composition patents	Potentially relevant to the active moiety, but likely aged relative to the 2019 approval
Salt or crystalline-form patents	Potentially relevant to ganirelix acetate manufacture and solid-state control
Injectable formulation patents	Could cover pH, tonicity, concentration, stability, or excipient combinations
Method-of-use patents	Could cover ovarian stimulation protocols or timing of GnRH-antagonist administration
Prefilled-syringe patents	Could cover container closure, needle systems, or delivery configuration
Manufacturing patents	Could cover peptide synthesis, purification, salt formation, or sterile filling

No conclusion about enforceable patent protection should be based solely on the brand name. Patent status depends on claims, terminal disclaimers, prosecution history, maintenance fees, Orange Book listing, and jurisdiction.

When does FYREMADEL lose exclusivity?

FYREMADEL received FDA approval in 2019. The product’s regulatory exclusivity period is distinct from patent term.

A 505(b)(2) or full NDA product may receive different exclusivity treatment depending on FDA’s determination of the application and the clinical investigations relied upon. Three-year exclusivity, where granted, generally protects approved conditions of use or dosage forms supported by new clinical investigations and does not block all possible abbreviated applications. Five-year new chemical entity exclusivity is generally reserved for an active moiety that has not previously been approved in the United States. [3]

Ganirelix had extensive prior international use before FYREMADEL’s U.S. approval. That history reduces the commercial likelihood that the U.S. product would rely on a new chemical entity exclusivity position. The practical U.S. barrier is therefore more likely to be patent-specific and regulatory rather than a long, standalone exclusivity period.

Exclusivity timeline

Event	Timing
FDA approval of FYREMADEL	2019
Potential three-year clinical-investigation exclusivity window	Could have extended into approximately 2022 if granted
Current commercial position	Mature injectable fertility product
Biosimilar exclusivity	Not applicable
Generic competition risk	Dependent on FDA application strategy, patents, and commercial economics

An exact exclusivity expiration date should not be inferred without the FDA exclusivity code and application history. The FDA’s Orange Book and Drugs@FDA records control the current regulatory position. [2,4]

What is the Orange Book status of FYREMADEL?

FYREMADEL is an FDA-approved drug product and should be evaluated through its FDA application number, product listing, and any associated patent or exclusivity entries.

For commercial diligence, the relevant questions are:

1. Is a patent listed against the FYREMADEL application?
2. Does the listed patent cover the formulation, method of use, or another aspect of the product?
3. What expiration date is recorded?
4. Is the product eligible for an abbreviated application pathway?
5. Have any Paragraph IV certifications or patent litigation been publicly reported?

A brand-level search is insufficient because ganirelix products may be listed under different application numbers, sponsors, or naming conventions.

Which companies are challenging FYREMADEL?

There is no established basis in the core public product information to identify a current Paragraph IV challenger or active Hatch-Waxman litigation directed specifically at FYREMADEL.

The principal competitive threat is not necessarily a direct patent challenge. It is substitution among gonadotropin-releasing hormone antagonists used in fertility protocols, including ganirelix products and cetrorelix acetate products.

Potential competitors include:

• generic or authorized-generic ganirelix injections;
• cetrorelix acetate products;
• imported or internationally sourced ganirelix products;
• fertility-treatment protocols using alternative stimulation strategies;
• clinic-preferred products supplied through specialty distributors.

A Paragraph IV filing would be commercially significant only if it targeted a listed patent or a patent position that materially blocked entry. In a small injectable market, litigation economics may be less attractive than in large chronic-care markets.

What formulation opportunities exist for FYREMADEL?

The most credible opportunities are incremental improvements that preserve the product’s clinical profile.

1. Prefilled-syringe optimization

A prefilled syringe is central to FYREMADEL’s usability. Development opportunities include:

• lower injection force;
• smaller-gauge needles;
• reduced dead volume;
• improved plunger-stop performance;
• enhanced labeling and dose visibility;
• needle-safety integration;
• compatibility with automated injection devices.

Any device modification would require assessment under FDA combination-product principles if the delivery system materially affects administration or performance.

2. Injection-site tolerability

Subcutaneous fertility injections are administered repeatedly during treatment cycles. Commercial differentiation may come from reducing pain, stinging, bruising, or local irritation.

Relevant variables include:

• solution pH;
• osmolality;
• buffer concentration;
• needle gauge and bevel;
• injection speed;
• silicone-oil level;
• extractables from elastomeric components;
• storage temperature at administration.

A formulation that improves tolerability without adding a new preservative could support physician and patient preference, although the clinical benefit would need to be demonstrated.

3. Alternative container systems

Potential container systems include:

• glass prefilled syringes;
• cyclic olefin polymer syringes;
• cyclic olefin copolymer cartridges;
• dual-component systems;
• ready-to-use unit-dose devices.

Polymer syringes could reduce breakage and support device integration. Glass may offer a more established regulatory history but can create risks involving breakage, tungsten residues, silicone oil, and delamination.

4. Refrigeration and supply-chain improvements

The current product labeling includes storage requirements that make temperature control relevant to fertility clinics and specialty pharmacies. [1]

Commercial opportunities include:

• improved refrigerated shelf life;
• validated excursion allowances;
• packaging that reduces temperature excursions;
• secondary packaging for clinic inventory;
• supply agreements with fertility networks;
• dual-source excipient and syringe qualification.

A more robust supply chain may have greater commercial value than a minor excipient change because treatment cycles are time-sensitive and clinic scheduling is inflexible.

5. Multi-dose or device-enabled presentations

A multi-dose presentation could reduce packaging and handling costs but would create substantial regulatory and microbiological issues. The current single-dose format avoids preservative exposure and repeated container entry.

A multi-dose product would need to address:

• antimicrobial preservation;
• sterility throughout in-use life;
• dose accuracy;
• contamination control;
• stability after first puncture;
• patient and clinic handling.

For this product, a unit-dose autoinjector may have a stronger commercial rationale than a conventional multi-dose vial.

How strong is the FYREMADEL patent estate?

The patent estate appears more likely to be moderate than dominant based on the product’s mature active ingredient, small-volume injectable formulation, and 2019 U.S. approval. The strongest potential protection would probably arise from narrowly drafted formulation, container, device, or manufacturing claims rather than broad exclusivity over ganirelix itself.

Estate component	Strategic strength
Active ingredient	Likely limited by age of ganirelix technology
Basic injectable formulation	Usually vulnerable to design-around strategies
Specific excipient ratios	Potentially useful if tied to stability or tolerability data
Prefilled syringe	Moderate if device claims are technically narrow and enforceable
Manufacturing process	Potentially strong if purification or impurity control is difficult to reproduce
Method of use	Variable; depends on claim scope and protocol overlap
Trade secrets	Potentially important for process controls and sterile filling

The strongest defensible position would combine formulation claims with device claims, process controls, and clinical-use evidence. A single excipient claim is unlikely to create a durable commercial barrier unless it produces a measurable technical effect.

What generic launch risks exist?

A generic or follow-on entrant would face several commercial barriers even if patent risk is limited.

Regulatory risk

The applicant must establish pharmaceutical equivalence and bioequivalence or otherwise satisfy FDA requirements for the chosen application pathway. Injectable products can require detailed evidence on sterility, particulate matter, container closure, extractables, impurities, and device performance.

Manufacturing risk

Ganirelix is a peptide-related active ingredient, making impurity control, purification, salt formation, and analytical characterization important. Sterile filling into prefilled syringes adds equipment, validation, and component-compatibility requirements.

Market-size risk

The fertility market is clinically important but narrower than major chronic-care markets. A second entrant may face:

• limited annual treatment cycles relative to mass-market drugs;
• concentrated purchasing through fertility clinics;
• payer and distributor contracting;
• price competition from existing alternatives;
• inventory risks because fertility-treatment demand is schedule-sensitive.

Commercial launch scenarios

Scenario	Likely commercial effect
No direct entrant	FYREMADEL retains price and clinic-positioning advantages
One approved generic	Moderate price erosion, especially in tenders and distributor contracts
Multiple generics	Greater price compression and substitution
Device-differentiated entrant	Potential premium despite equivalent active ingredient
Supply disruption	Rapid opportunity for alternate suppliers with validated inventory
Formulation-improved entrant	Possible preference-based adoption if tolerability or usability improves

How does FYREMADEL compare with cetrorelix products?

Factor	FYREMADEL	Cetrorelix products
Drug class	GnRH antagonist	GnRH antagonist
Active ingredient	Ganirelix acetate	Cetrorelix acetate
Administration	Subcutaneous	Subcutaneous
Primary use	Controlled ovarian stimulation	Controlled ovarian stimulation
Formulation opportunity	Prefilled syringe and excipient optimization	Reconstitution and presentation optimization may be more relevant, depending on product
Substitution	Protocol and physician dependent	Protocol and physician dependent
Patent risk	Product- and claim-specific	Product- and claim-specific
Commercial differentiation	Convenience, tolerability, supply	Protocol fit, availability, price

The practical competitive decision is often driven by clinic protocol, supplier reliability, reimbursement, and ease of administration rather than by pharmacology alone.

What licensing deals could create value?

Licensing opportunities are most credible in four areas:

1. Device licensing: autoinjectors, low-force syringe systems, needle-safety devices, and polymer containers.
2. Formulation licensing: improved pH control, stability, or injection tolerability.
3. Manufacturing licensing: ganirelix purification, sterile filling, and high-throughput prefilled-syringe production.
4. Commercial licensing: regional distribution rights, fertility-clinic contracts, and specialty-pharmacy access.

A deal based only on access to ganirelix API would have limited differentiation unless it includes supply security, regulatory documentation, or a protected manufacturing process.

What geographic markets offer the best opportunities?

The strongest opportunities are markets with established assisted-reproduction volumes, specialist fertility clinics, and reimbursement or private-pay capacity.

Relevant regions include:

• United States;
• Western Europe;
• Japan;
• Australia;
• Canada;
• Gulf fertility markets;
• selected Latin American markets.

Geographic expansion requires country-specific review of:

• marketing authorization;
• patent and supplementary protection certificate status;
• device registration;
• import controls;
• cold-chain requirements;
• fertility-treatment reimbursement;
• local pharmacovigilance obligations.

A U.S. strategy should center on FDA application status, Orange Book listings, and specialty-distribution access. European commercialization requires separate review of national authorization, centralized or decentralized procedures, and country-level substitution rules.

Key Takeaways

• FYREMADEL is a single-dose, subcutaneous ganirelix acetate injection containing mannitol, acetic acid, sodium hydroxide, and water for injection.
• The main commercial opportunities are prefilled-syringe design, injection tolerability, stability, packaging, and supply reliability.
• A broad active-ingredient patent barrier is unlikely to be the main strategic issue for a mature ganirelix product.
• Formulation and device claims may provide more practical differentiation than composition claims.
• Biosimilar analysis is not applicable because FYREMADEL is a chemically defined injectable rather than a biologic.
• Generic-entry economics may be constrained by the relatively specialized fertility market.
• A device-enabled or better-tolerated product could command more value than a formulation with only an excipient substitution.
• Orange Book and Drugs@FDA records remain the controlling sources for current patent listings, exclusivity codes, and application status.

FAQs

Is FYREMADEL preservative-free?

Yes. The labeled formulation lists mannitol, acetic acid, sodium hydroxide, and water for injection. It is supplied as a single-dose injection rather than a preserved multi-dose product. [1]

Can the FYREMADEL formulation use phosphate buffer instead of acetate?

A phosphate-buffered version would be a formulation change requiring stability, compatibility, impurity, sterility, and regulatory assessment. It should not be treated as an interchangeable formulation solely because the active ingredient and strength remain unchanged.

Is a ganirelix prefilled syringe eligible for a biosimilar pathway?

No. Biosimilar pathways apply to biological products. Ganirelix acetate is evaluated through drug-product pathways, including applicable abbreviated or hybrid application routes.

What is the highest-value excipient opportunity for a FYREMADEL competitor?

The highest-value opportunity is likely a formulation and device combination that improves injection tolerability, dose delivery, and storage robustness without adding a preservative or increasing administration complexity.

Could a multi-dose FYREMADEL product reduce manufacturing cost?

It could reduce packaging and handling costs, but it would introduce preservative, in-use stability, sterility, contamination, and dose-accuracy requirements. A single-dose autoinjector may offer a more practical commercial improvement.

References

1. U.S. Food and Drug Administration. (2019). FYREMADEL (ganirelix acetate) injection, prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). Small business assistance: Frequently asked questions for new drug product exclusivity. https://www.fda.gov/

4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/